Wells Fargo & Company Upgrades Zealand Pharma A/S (OTCMKTS:ZLDPF) to "Strong-Buy"

Key Points

• Zealand Pharma A/S was upgraded to a "strong-buy" rating by both Wells Fargo & Company and Barclays, reflecting growing analyst confidence in the stock.
• The company's current stock price is $61.06, and it has a market cap of $4.34 billion, with a P/E ratio of -24.52.
• Despite a recent earnings report showing a loss of $0.67 EPS, Zealand Pharma outperformed analysts' expectations by beating the consensus estimate by $0.10.

Wells Fargo & Company upgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) to a strong-buy rating in a research report report published on Thursday,Zacks.com reports.

Several other equities analysts have also recently commented on the stock. BNP Paribas raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Tuesday, July 1st. Barclays upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday, July 7th. One analyst has rated the stock with a buy rating and five have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Strong Buy".

Zealand Pharma A/S Price Performance

Zealand Pharma A/S stock remained flat at $61.06 during mid-day trading on Thursday. The company's stock had a trading volume of 3 shares, compared to its average volume of 295. The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. Zealand Pharma A/S has a 52-week low of $54.95 and a 52-week high of $141.74. The company has a 50 day moving average price of $62.19 and a 200 day moving average price of $75.68.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.10. The firm had revenue of $1.14 million for the quarter, compared to analysts' expectations of $248.61 million. Zealand Pharma A/S had a negative net margin of 2,127.09% and a negative return on equity of 13.40%. As a group, research analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.